News

The Pharma Letter10m
Patient death in Brazil not related to Elevidys, Sarepta says
The US Food and Drug Administration (FDA) issued a press release late Friday announcing an investigation into the death of an ...
Sarepta Therapeutics: Beaten Down, But Not Out
Sarepta Therapeutics now trades at book value with strong cash and cost-cutting plans, while ELEVIDYS may regain broader use.
Stocktwits on MSN7h
Retail Bulls Stick With Sarepta After 8-Year-Old Patient’s Death Deemed Unrelated To DMD Gene Therapy
Retail sentiment around Sarepta Therapeutics remained upbeat on Monday after the company said Friday that the death of an ...
Wall Street Brunch: Four Mag 7 Earnings And Fed On Tap
The Fed is expected to keep rates steady, but Powell will get questions on Fed independence. Apple, Microsoft, Meta and ...
TipRanks on MSN18h
Sarepta says eight-year-old death deemed unrelated to Elevidys
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...
GEN - Genetic Engineering and Biotechnology News22h
FDA Probes Death of Brazilian Boy Linked to Sarepta’s Elevidys
The FDA is investigating the death last month of an eight-year-old boy in Brazil who had received Sarepta Therapeutics’ Elevidys® (delandistrogene moxeparvovec-rokl)—though the company and its ...